Key result
The presence of anti-THPO antibody (detected in 13 of 82 patients) was significantly associated with a lower average platelet count in patients with type 2 diabetes.
Why the study?
Anti-THPO antibody relates to thrombocytopenia, but its prevalence and relationship with platelet count had not been reported in patients with type 2 diabetes mellitus.
Does the presence of anti-THPO antibody affect platelet count in patients with type 2 diabetes mellitus?
Cross-Sectional (n=82)
Does the presence of anti-THPO antibody affect platelet count in patients with type 2 diabetes mellitus?
The presence of anti-THPO antibodies in patients with type 2 diabetes is associated with a significantly lower platelet count.
Anti-THPO antibodies were associated with lower platelet counts in type 2 diabetes; hypothesis-generating and should not yet change practice.
Thrombopoietin (THPO) is a circulatory cytokine that plays an important role in platelet production. The presence of anti-THPO antibody relates to thrombocytopenia and is rarely seen in hematopoietic and autoimmune diseases. To date, there had been no reports that focused on the anti-THPO antibody in patients with type 2 diabetes mellitus (T2DM). To evaluate prevalence of the anti-THPO antibody in patients with T2DM and the relationship between anti-THPO antibody and platelet count, a cross-sectional study was performed on 82 patients with T2DM. The anti-THPO antibody was measured by ELISA using preserved sera and detected in 13 patients. The average platelet count was significantly lower in patients with the anti-THPO antibody than in those without the anti-THPO antibody. Multivariate linear regression analyses showed a significant relationship between the anti-THPO antibody and platelet count, after adjusting for other variables. To our best knowledge, this was the first report on the effect of the anti-THPO antibody on platelet count in patients with T2DM. Further investigation is needed to validate the prevalence and pathological significance of the anti-THPO antibody in patients with T2DM.
No takes yet. Share an insight, caveat, or question.
Fukuda et al. (2020) conducted a cross-sectional in Type 2 diabetes mellitus (T2DM) (n=82). Anti-THPO antibody presence vs. Absence of anti-THPO antibody was evaluated on Platelet count. The presence of anti-THPO antibody (detected in 13 of 82 patients) was significantly associated with a lower average platelet count in patients with type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: